NASDAQ:IBB - iShares Nasdaq Biotechnology ETF Stock Price, Price Target & More

$102.8539 -0.42 (-0.41 %)
(As of 04/25/2018 12:09 PM ET)
Previous Close$103.27
Today's Range$102.31 - $103.98
52-Week Range$94.20 - $119.30
Volume896,847 shs
Average Volume2.96 million shs
Market Capitalization$8.71 billion
P/E RatioN/A
Dividend Yield0.41%
Beta1.34

About iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

iShares Nasdaq Biotechnology ETF logoiShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Receive IBB News and Ratings via Email

Sign-up to receive the latest news and ratings for IBB and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Blackrock
Fund NameiShares Nasdaq Biotechnology ETF
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:IBB
Inception Date2/5/2001
Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkNASDAQ Biotechnology TR USD
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$8.90 billion
Average Daily Volume$2.74 million
Discount/Premium-1.41%

ETF Expenses

Management Fee0.47%
Other Expenses0.00%
Total Expenses0.47%
Fee Waiver0.00%
Net Expenses0.47%

Administrator, Advisor and Custodian

AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial

How to Become a New Pot Stock Millionaire

iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Frequently Asked Questions

What is iShares Nasdaq Biotechnology ETF's stock symbol?

iShares Nasdaq Biotechnology ETF trades on the NASDAQ under the ticker symbol "IBB."

How often does iShares Nasdaq Biotechnology ETF pay dividends? What is the dividend yield for iShares Nasdaq Biotechnology ETF?

iShares Nasdaq Biotechnology ETF declared a quarterly dividend on Thursday, December 21st. Investors of record on Friday, December 22nd will be given a dividend of $0.125 per share on Thursday, December 28th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.49%. The ex-dividend date is Thursday, December 21st. This is a boost from iShares Nasdaq Biotechnology ETF's previous quarterly dividend of $0.04. View iShares Nasdaq Biotechnology ETF's Dividend History.

When did iShares Nasdaq Biotechnology ETF's stock split? How did iShares Nasdaq Biotechnology ETF's stock split work?

iShares Nasdaq Biotechnology ETF shares split on the morning of Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly minted shares were issued to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of iShares Nasdaq Biotechnology ETF stock prior to the split would have 300 shares after the split.

Who are some of iShares Nasdaq Biotechnology ETF's key competitors?

Who are iShares Nasdaq Biotechnology ETF's key executives?

iShares Nasdaq Biotechnology ETF's management team includes the folowing people:
  • George G. C. Parker Ph.D., Independent Chairman of the Board of Trustees
  • Michael Arthur Latham, President, Trustee
  • Jack Gee, Chief Financial Officer, Treasurer
  • Geoffrey D. Flynn, Chief Operating Officer, Executive Vice President
  • , Bio & Compensation - 
  • Amy Schioldager, Executive Vice President
  • Ira P. Shapiro, Vice President, Chief Legal Officer
  • Matt Tucker, Vice President
  • , Bio & Compensation - 
  • Eilleen M. Clavere, Secretary
  • Cecilia H. Herbert, Independent Trustee
  • Charles A. Hurty, Independent Trustee

Has iShares Nasdaq Biotechnology ETF been receiving favorable news coverage?

Headlines about IBB stock have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. iShares Nasdaq Biotechnology ETF earned a daily sentiment score of 0.01 on Accern's scale. They also gave press coverage about the financial services provider an impact score of 45.02 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of iShares Nasdaq Biotechnology ETF?

Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is iShares Nasdaq Biotechnology ETF's stock price today?

One share of IBB stock can currently be purchased for approximately $102.8539.

How big of a company is iShares Nasdaq Biotechnology ETF?

iShares Nasdaq Biotechnology ETF has a market capitalization of $8.71 billion.


MarketBeat Community Rating for iShares Nasdaq Biotechnology ETF (IBB)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  141
MarketBeat's community ratings are surveys of what our community members think about iShares Nasdaq Biotechnology ETF and other stocks. Vote "Outperform" if you believe IBB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IBB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/ABuyBuy
Consensus Rating Score: N/AN/A3.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Consensus Price Target History

Price Target History for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)
Show:

Earnings

Dividends

iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Dividend Information

iShares Nasdaq Biotechnology ETF pays an annual dividend of $0.42 per share, with a dividend yield of 0.41%. IBB's most recent quarterly dividend payment was Thursday, December 28.
Most Recent Dividend:12/28/2017
Annual Dividend:$0.42
Dividend Yield:0.41%
Payout Ratio:N/A
Dividend Payments by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/21/2017Quarterly$0.12500.47%12/21/201712/22/201712/28/2017
9/26/2017Quarterly$0.03970.14%9/26/20179/27/20179/29/2017
6/27/2017quarterly$0.05890.23%6/27/20176/29/20176/30/2017
3/24/2017quarterly$0.09970.41%3/24/20173/28/20173/30/2017
12/22/2016quarterly$0.03060.14%12/22/201612/27/201612/29/2016
6/24/2015quarterly$0.01930.06%6/24/20156/26/20156/30/2015
(Data available from 1/1/2013 forward)

Insider Trades

Headlines

iShares Nasdaq Biotechnology ETF (NASDAQ IBB) News Headlines

Source:
DateHeadline
Why Biogens Stock Rebound Is Good News for BiotechsWhy Biogen's Stock Rebound Is Good News for Biotechs
finance.yahoo.com - April 25 at 8:06 AM
WhiteHorse Finance (WHF) and iShares Nasdaq Biotechnology ETF (IBB) Head-To-Head ComparisonWhiteHorse Finance (WHF) and iShares Nasdaq Biotechnology ETF (IBB) Head-To-Head Comparison
www.americanbankingnews.com - April 20 at 11:16 PM
iShares Nasdaq Biotechnology ETF (IBB) & MVC Capital (MVC) Financial ReviewiShares Nasdaq Biotechnology ETF (IBB) & MVC Capital (MVC) Financial Review
www.americanbankingnews.com - April 20 at 9:38 PM
4 Beaten-Down Funds Set to Soar (with dividends up to 10.9%)4 Beaten-Down Funds Set to Soar (with dividends up to 10.9%)
www.nasdaq.com - April 20 at 5:32 PM
No Bid Coming for Shire ReportedlyNo Bid Coming for Shire Reportedly
finance.yahoo.com - April 19 at 5:52 PM
Could Big Biotech Earnings Be a Bust?Could Big Biotech Earnings Be a Bust?
www.barrons.com - April 18 at 5:56 PM
Biotech Sector Could See New LifeBiotech Sector Could See New Life
finance.yahoo.com - April 4 at 4:26 PM
Alkermes gets refusal letter from FDA regarding NDA for depression treatment; shares haltedAlkermes gets 'refusal' letter from FDA regarding NDA for depression treatment; shares halted
www.marketwatch.com - April 2 at 8:11 AM
Bank Loan Data Suggests The Top Is InBank Loan Data Suggests The Top Is In
seekingalpha.com - March 30 at 8:06 AM
Incyte’s Jakafi in 2017Incyte’s Jakafi in 2017
finance.yahoo.com - March 26 at 8:08 AM
RSI Alert: Celgene (CELG) Now OversoldRSI Alert: Celgene (CELG) Now Oversold
www.nasdaq.com - March 24 at 5:26 PM
Cramers charts show signs of life for the struggling biotech sectorCramer's charts show 'signs of life' for the struggling biotech sector
www.cnbc.com - March 22 at 5:48 PM
In The Spotlight: G1 Therapeutics - NasdaqIn The Spotlight: G1 Therapeutics - Nasdaq
www.nasdaq.com - March 22 at 8:10 AM
New Opportunities in Biotech: Cramers Off the Charts - TheStreet.comNew Opportunities in Biotech: Cramer's 'Off the Charts' - TheStreet.com
www.thestreet.com - March 22 at 8:10 AM
Tocagen Drug Candidate Looks Undervalued, But Very RiskyTocagen Drug Candidate Looks Undervalued, But Very Risky
seekingalpha.com - March 21 at 5:50 PM
Chopping a Way Back for the Bull: Cramers Mad Money Recap ... - TheStreet.comChopping a Way Back for the Bull: Cramer's 'Mad Money' Recap ... - TheStreet.com
www.thestreet.com - March 21 at 8:22 AM
Cramer's charts show 'signs of life' for the struggling b...Cramer's charts show 'signs of life' for the struggling b...
finance.yahoo.com - March 21 at 8:22 AM
Cramer Remix: Here's how Mark Zuckerberg should respond t...Cramer Remix: Here's how Mark Zuckerberg should respond t...
finance.yahoo.com - March 21 at 8:22 AM
Cramer: These charts show 'signs of life' for biotechCramer: These charts show 'signs of life' for biotech
finance.yahoo.com - March 21 at 8:22 AM
Try This ETF Pair To Round Out Your Biotech Exposure - Seeking AlphaTry This ETF Pair To Round Out Your Biotech Exposure - Seeking Alpha
seekingalpha.com - March 16 at 8:05 AM
In The Spotlight: Biohaven Pharma - NasdaqIn The Spotlight: Biohaven Pharma - Nasdaq
www.nasdaq.com - March 7 at 8:04 AM
M&R Capital Management Inc. Grows Position in iShares NASDAQ Biotechnology Index (IBB)M&R Capital Management Inc. Grows Position in iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - March 6 at 2:58 PM
Scotia Capital Inc. Has $8.40 Million Stake in iShares NASDAQ Biotechnology Index (IBB)Scotia Capital Inc. Has $8.40 Million Stake in iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - March 6 at 2:17 PM
Stock Market News for March 5, 2018 - NasdaqStock Market News for March 5, 2018 - Nasdaq
www.nasdaq.com - March 6 at 8:04 AM
iShares NASDAQ Biotechnology Index (IBB) Holdings Lifted by Eaton Vance ManagementiShares NASDAQ Biotechnology Index (IBB) Holdings Lifted by Eaton Vance Management
www.americanbankingnews.com - March 5 at 10:58 AM
iShares NASDAQ Biotechnology Index (IBB) Position Decreased by Lombard Odier Asset Management Switzerland SAiShares NASDAQ Biotechnology Index (IBB) Position Decreased by Lombard Odier Asset Management Switzerland SA
www.americanbankingnews.com - March 4 at 2:39 PM
Calamos Advisors LLC Grows Position in iShares NASDAQ Biotechnology Index (IBB)Calamos Advisors LLC Grows Position in iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - March 2 at 5:19 AM
Sorry Celgene. Bigger Isn’t Better in Biotech.Sorry Celgene. Bigger Isn’t Better in Biotech.
www.barrons.com - March 1 at 6:01 PM
In The Spotlight: ARMO BioSciences - NasdaqIn The Spotlight: ARMO BioSciences - Nasdaq
www.nasdaq.com - March 1 at 8:04 AM
iShares NASDAQ Biotechnology Index (IBB) Shares Bought by CLS Investments LLCiShares NASDAQ Biotechnology Index (IBB) Shares Bought by CLS Investments LLC
www.americanbankingnews.com - February 28 at 1:47 PM
Tetraphase Pharmaceuticals Trial Failure May Mask Value - Seeking AlphaTetraphase Pharmaceuticals Trial Failure May Mask Value - Seeking Alpha
seekingalpha.com - February 28 at 8:04 AM
iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Brown Advisory Inc.iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Brown Advisory Inc.
www.americanbankingnews.com - February 28 at 5:14 AM
iShares NASDAQ Biotechnology Index (IBB) Holdings Boosted by Ashfield Capital Partners LLCiShares NASDAQ Biotechnology Index (IBB) Holdings Boosted by Ashfield Capital Partners LLC
www.americanbankingnews.com - February 28 at 4:46 AM
Suntrust Banks Inc. Has $3.43 Million Position in iShares NASDAQ Biotechnology Index (IBB)Suntrust Banks Inc. Has $3.43 Million Position in iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - February 27 at 4:26 PM
iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Clal Insurance Enterprises Holdings LtdiShares NASDAQ Biotechnology Index (IBB) Shares Bought by Clal Insurance Enterprises Holdings Ltd
www.americanbankingnews.com - February 27 at 3:37 PM
Commerce Bank Has $84.70 Million Holdings in iShares NASDAQ Biotechnology Index (IBB)Commerce Bank Has $84.70 Million Holdings in iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - February 27 at 9:34 AM
iShares NASDAQ Biotechnology Index (IBB) Holdings Raised by Financial Counselors Inc.iShares NASDAQ Biotechnology Index (IBB) Holdings Raised by Financial Counselors Inc.
www.americanbankingnews.com - February 27 at 7:30 AM
Oak Grove Capital LLC Buys New Position in iShares NASDAQ Biotechnology Index (IBB)Oak Grove Capital LLC Buys New Position in iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - February 26 at 3:55 PM
Private Management Group Inc. Buys 56,627 Shares of iShares NASDAQ Biotechnology Index (IBB)Private Management Group Inc. Buys 56,627 Shares of iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - February 26 at 3:10 PM
ETF Preview: ETFs, Futures Point Lower as Fed Meeting Minutes Indicate Likelihood of More Interest Rate Hikes - NasdaqETF Preview: ETFs, Futures Point Lower as Fed Meeting Minutes Indicate Likelihood of More Interest Rate Hikes - Nasdaq
www.nasdaq.com - February 24 at 8:03 AM
Mid-Day ETF Update: ETFs, Stocks Extend Gains on Fed Speak and Pull Back in Treasury Yields - NasdaqMid-Day ETF Update: ETFs, Stocks Extend Gains on Fed Speak and Pull Back in Treasury Yields - Nasdaq
www.nasdaq.com - February 24 at 8:03 AM
Mid-Day ETF Update: ETFs, Stocks Higher as Street Shrugs Off Concerns for Possible Fed Interest Rate Hikes - NasdaqMid-Day ETF Update: ETFs, Stocks Higher as Street Shrugs Off Concerns for Possible Fed Interest Rate Hikes - Nasdaq
www.nasdaq.com - February 23 at 8:06 AM
iShares NASDAQ Biotechnology Index (IBB) versus Cannae (CNNE) Head to Head SurveyiShares NASDAQ Biotechnology Index (IBB) versus Cannae (CNNE) Head to Head Survey
www.americanbankingnews.com - February 18 at 11:08 PM
iShares NASDAQ Biotechnology Index (IBB) & Cannae (CNNE) Head-To-Head ComparisoniShares NASDAQ Biotechnology Index (IBB) & Cannae (CNNE) Head-To-Head Comparison
www.americanbankingnews.com - February 16 at 1:34 PM
3 Biotechs That Resisted The Recent Crash And Why - Seeking Alpha3 Biotechs That Resisted The Recent Crash And Why - Seeking Alpha
seekingalpha.com - February 16 at 8:07 AM
Reata Pharmaceuticals A Buy On Bardoxolene DataReata Pharmaceuticals A Buy On Bardoxolene Data
seekingalpha.com - February 14 at 3:39 PM
Mid-Day ETF Update: ETFs, Stocks Extend Gains as Trump Unveils Budget, Infrastructure Plan - NasdaqMid-Day ETF Update: ETFs, Stocks Extend Gains as Trump Unveils Budget, Infrastructure Plan - Nasdaq
www.nasdaq.com - February 12 at 3:36 PM
Teva Pharmaceutical Industries Ltd (ADR) Stock Is About to Spike - Investorplace.comTeva Pharmaceutical Industries Ltd (ADR) Stock Is About to Spike - Investorplace.com
investorplace.com - February 12 at 3:36 PM
Mid-Day ETF Update: ETFs, Stocks Resume Losses as Volatility, Concern Over Fed Hikes Eclipse Trade Data - NasdaqMid-Day ETF Update: ETFs, Stocks Resume Losses as Volatility, Concern Over Fed Hikes Eclipse Trade Data - Nasdaq
www.nasdaq.com - February 10 at 3:37 PM
Comparing Cannae (CNNE) & iShares NASDAQ Biotechnology Index (IBB)Comparing Cannae (CNNE) & iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - February 8 at 11:35 AM

SEC Filings

iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

iShares Nasdaq Biotechnology ETF (NASDAQ IBB) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.